A 70276
Latest Information Update: 01 Feb 2013
At a glance
- Originator Abbott Laboratories
 - Class
 - Mechanism of Action Cholecystokinin A receptor antagonists
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 
Highest Development Phases
- Discontinued Cholestasis
 
Most Recent Events
- 17 Oct 1994 No-Development-Reported for Cholestasis in USA (Unknown route)